or adding the selective CaR activator NPS R-467 elicited rapid, dose-dependent phosphorylation of ERK1/2. These phosphorylations were attenuated by pretreatment with pertussis toxin (PTX) or by treatment with the phosphotyrosine kinase (PTK) inhibitors genistein and herbimycin, the phosphatidylinositol-specific phospholipase C (PI-PLC) inhibitor U-73122, or the protein kinase C (PKC) inhibitor GF109203X and were enhanced by the PKC activator phorbol 12-myristate 13-acetate. Combined treatment with PTX and inhibitors of both PKC and PTK nearly abolished high Ca o 2ϩ -evoked ERK1/2 activation in HEKCaR cells, demonstrating CaR-mediated coupling via both G q and G i . High Ca o 2ϩ increased serine phosphorylation of the 85-kDa cytosolic phospholipase A 2 (cPLA 2 ) in both parathyroid and HEKCaR cells. The selective mitogen-activated protein kinase (MAPK) inhibitor PD98059 abolished high-Ca o 2ϩ -induced ERK1/2 activation and reduced cPLA 2 phosphorylation in both cell types, documenting MAPK's role in cPLA 2 activation. Thus our data suggest that the CaR activates MAPK through PKC, presumably through G q/11 -mediated activation of PI-PLC, as well as through G i -and PTK-dependent pathway(s) in bovine parathyroid and HEKCaR cells and indicate the importance of MAPK in cPLA 2 activation. calcium-sensing receptor; mitogen-activated protein kinase; signal transduction; phospholipase A 2 ; kidney THE PARATHYROID GLANDS play an essential role in mineral ion homeostasis by virtue of their capacity to recognize and respond to (i.e., sense) small changes in the extracellular ionized calcium concentration (Ca o 2ϩ ) (4, 5) . Parathyroid hormone (PTH) secretion is reduced, and renal Ca 2ϩ excretion is increased, at high Ca o 2ϩ , processes mediated by a recently characterized cell surface Ca o 2ϩ -sensing receptor (CaR) (6; for reviews, see Refs. 7, 8) . The CaR is a member of the superfamily of G protein-coupled receptors (GPCRs) and has a large extracellular domain that binds Ca o 2ϩ and other polycationic CaR agonists such as magnesium, gadolinium, and neomycin. The CaR controls multiple signaling pathways (6, 8, 24, 25, 35) . Ligand binding results in G protein-dependent activation of phosphatidylinositol-specific phospholipase C (PI-PLC), causing accumulation of inositol 1,4,5-trisphosphate (IP 3 ) and 1,2-sn-diacylglycerol and promoting rapid release of Ca 2ϩ from its intracellular stores (8, 15, 26, 46) . CaR-mediated activation of PI-PLC in parathyroid and human embryonic kidney cells (HEK293) stably transfected with the human CaR (HEKCaR) appears to be a direct, G protein-mediated process, probably involving Gq/11, since this effect is not blocked by pertussis toxin (PTX) (8) . Activation of phospholipases A 2 (PLA 2 ) and D by high Ca o 2ϩ are probably indirect, utilizing CaR-mediated, PLC-dependent activation of protein kinase C (PKC) (8, 24) . High Ca o 2ϩ -elicited, CaR-induced activation of these intracellular signaling pathways is thought to cause the associated decrease in the rate of PTH secretion from the parathyroid cell.
Studies of inherited disorders of Ca o 2ϩ sensing have established the CaR's central role in Ca o 2ϩ homeostasis. Inactivating CaR mutations cause an increase in the set point for Ca o 2ϩ -regulated PTH secretion and promote excessive renal tubular Ca o 2ϩ reabsorption in the hypercalcemic disorders, familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism (1, 7, 8) . Conversely, activating mutations produce a form of autosomal dominant hypocalcemia with inappropriately normal or low PTH levels and excessive renal Ca 2ϩ excretion at any given level of Ca o 2ϩ (1, 7, 8) . Abnormal Ca o 2ϩ sensing in hyperparathyroidism (i.e., due to parathyroid adenoma or severe uremic hyperparathyroidism) is associated with reduced expression of the CaR protein (27) . The selective calcimimetic CaR activator NPS R-568 effectively inhibits PTH secretion and concomitantly reduces serum calcium concentration in hyperparathyroid patients (38) .
The mitogen-activated protein kinase (MAPK) pathways are found ubiquitously in eukaryotic organisms (16) . The MAPK are serine/threonine-specific protein kinases and include the extracellular signal-regulated kinases ERK1 and ERK2, the cJun NH 2 -terminal kinases, and the p38-MAP kinases (16, 20, 21) . MAPKs are regulated and activated by dual tyrosine and threonine phosphorylation (20, 28) . Phosphorylated, activated ERK1/2 can phosphorylate cytosolic protein substrates [e.g., cytosolic phospholipase A 2 (cPLA 2 )] (22, 29, 30) and also translocate to the nucleus, where they phosphorylate and activate nuclear transcription factors (16, 20, 29) .
Early studies of the biological roles of MAPK emphasized their capacities to regulate cell growth and differentiation. However, more recent work has revealed that they regulate a wide variety of processes, including not only gene expression (e.g., by phosphorylating nuclear transcription factors) but also the activity of various enzymes [e.g., cPLA 2 (22, 29, 30) and cAMP phosphodiesterase (34)] and ion channels [i.e., K ϩ channels (33) and chloride currents (49) ]. Therefore, the MAPKs are pleiotropic regulators of numerous cellular activities.
In addition to being activated by various growth factors and cytokines such as epidermal growth factor (39) and interleukin-1 (37), the MAPKs are also activated by many G protein-coupled receptors (GPCRs) (16, 20) . There are several mechanisms by which GPCRs stimulate ERK. In COS-7 cells, lysophosphatidic acid (LPA) potently stimulates MAPK through PTX-sensitive, G i -linked LPA receptors (17, 32) . Activation of other G i -linked receptors, such as the M 2 muscarinic receptor, is believed to stimulate MAP kinase through G i -␤␥-subunits acting on a Ras-and Raf-dependent pathway (21, 31, 48) . In Chinese hamster ovary cells, inhibitors of phosphatidylcholine-specific phospholipase C (PC-PLC) and phosphatidylinositol 3-kinase (PI 3K) diminish activation of ERK2 through PTX-sensitive, G i -linked receptors (13) . Furthermore, G-␤␥-subunits stimulate MAPK activity by activating Src-family tyrosine kinases, promoting the phosphorylation of Shc and recruiting Grb2 and Sos complexes to the plasma membrane (31, 32) . cAMP inhibits MAPK in many cells (48) yet activates the enzyme in others (11, 48) . In contrast, receptors coupled to PTX-insensitive G proteins stimulate ERK predominantly via a tyrosine kinase-independent pathway mediated by PKC (16, 17, 20) .
Little information is available on the regulation of the MAPK pathway by the CaR, although McNeil et al. (36) have recently shown that this receptor stimulates ERK1 kinase activity and cellular proliferation in rat-1 fibroblasts. High Ca o 2ϩ is known to regulate PLA 2 in both kidney and parathyroid (2, 3, 24, 43, 44 (1, 24) was kindly provided by Dr. Kimberly Rogers of NPS Pharmaceuticals and was selected by hygromycin resistance. We have previously shown (1) that nontransfected HEK293 cells do not express an endogenous CaR, whereas transfected HEK293 cells (HEKCaR) express the CaR protein on the cell surface at high levels and are responsive to addition of CaR agonists to the ambient medium. Cells were grown in DMEM with 10% fetal bovine serum, without sodium pyruvate, either without (wild-type HEK293 cells) or with 200 g/ml hygromycin (HEKCaR cells). Before stimulation, subconfluent cell monolayers were serum starved in DMEM supplemented with 0.2% BSA (cell culture tested; Sigma) for 24 h. After aspiration of the culture media, the cells were incubated with the various reagents detailed in
RESULTS.
Western blot analysis. For the determination of ERK1/2 phosphorylation, parathyroid cells and monolayers of serumstarved HEKCaR and HEK293 cells were incubated at 37°C in serum-free medium containing 0.2% BSA, with varying concentrations of Ca o 2ϩ or of NPS R-467 or NPS S-467 at 1.0 mM Ca o 2ϩ , after preincubation with inhibitors of various signal transduction pathways, as described in RESULTS. At the end of the incubation period, the medium was removed, the cells were washed with ice-cold phosphate-buffered saline (PBS) containing 1 mM sodium vanadate, and 100 l of ice-cold lysis buffer were added [20 mM Tris ⅐ HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 25 mM NaF, 1% Triton X-100, 10% glycerol, 1 mM dithiothreitol, 1 mM freshly prepared sodium vanadate, 50 mM ␤-glycerophosphate, and protease inhibitors (10 g/ml each of aprotinin, leupeptin, soybean trypsin inhibitor, pepstatin, and calpain inhibitor, as well as 100 g/ml Pefabloc)] and were frozen immediately on dry ice (25, 27) . After thawing and homogenization, lysates were centrifuged at 10,000 g for 5 min at 4°C. Equal amounts of supernatant proteins (10-15 g) were separated by SDS-PAGE, and Western blot analysis was performed as described previously (25, 27) and in more detail below. Alternatively, cells were lysed directly with 100 l/ well of Laemmli sample buffer, cell lysates were sonicated briefly, and proteins were resolved by SDS-PAGE. The separated proteins were transferred electrophoretically onto nitrocellulose membranes (Schleicher and Schuell) and incubated with blocking solution (10 mM Tris ⅐ HCl, pH 7.4, 150 mM NaCl, and 0.05% Tween-20) containing 5% dry milk for 1 h at room temperature. ERK1/2 phosphorylation was detected by immunoblotting using a 3-h incubation with a 1:1,000 dilution of a rabbit polyclonal phospho-ERK1/2-specific antiserum and a subsequent incubation with a second, goat anti-rabbit, peroxidase-linked antiserum diluted in blocking solution. The bands were visualized by chemiluminescence (Renaissance enhanced chemiluminescence system). Quantitative comparisons of the phosphorylation of ERK1/2 under various experimental conditions were performed using an ImageQuant and a Personal Densitometer (Molecular Dynamics). Nitrocellulose membranes were stripped of antibodies and reprobed using an antiserum to ERK2 that detects this protein independently of its state of phosphorylation to confirm equal loading of ERK proteins. Protein concentrations were measured using the Micro BCA protein kit (Pierce).
Immunoprecipitation. Immunoprecipitation was performed to detect phospholipase A 2 as before (25) . Cells were washed with ice-cold PBS containing 1.0 mM sodium vanadate, lysed with lysis buffer (as described above), and centrifuged at 10,000 g for 10 min. Equal amounts of supernatant proteins (150 g of total cell lysate) were incubated with 5 g of anti-cPLA 2 monoclonal antibody (see RESULTS) for 1 h at 4°C, followed by addition of protein A-Sepharose beads for 1 h. Bound immune complexes were washed three times with lysis buffer, and the pellet was eluted by boiling for 5 min with 2ϫ Laemmli sample buffer (25, 27) . Supernatant proteins were separated by SDS-PAGE, transferred to nitrocellulose filters, and immunoblotted with anti-cPLA 2 and antiphosphoserine antibodies.
Statistics. The data are presented as means Ϯ SE of the indicated number of experiments. Statistical analyses were carried out using the unpaired Student's t-test when two groups were compared or with ANOVA, Bonferroni's method, or Dunn's one-way ANOVA on ranks when three or more groups were compared or multiple comparisons were carried out with a single control. A P value of Ͻ0.05 was considered to indicate a statistically significant difference.
RESULTS

Phosphorylation of ERK1/2 in response to elevated
Ca o 2ϩ in bovine parathyroid cells. Figure 1 shows that high Ca o 2ϩ increased the phosphorylation of ERK1/2 in a time-and dose-dependent manner, as assessed by use of a phospho-ERK1/2-specific polyclonal antiserum. The phosphorylation of ERK1/2 peaked at 10 min after raising the level of Ca o 2ϩ , decreased to the basal value after 1 h, and remained at that level for as long as 24 h. Figure 1B in "standard medium" at 37°C for the times indicated. A: ERK1/2 phosphorylation (P-ERK1/2) was measured using Western blotting with a phospho-ERK1/2-specific antiserum and an anti-ERK2 antiserum recognizing both phosphorylated and nonphosphorylated forms of the enzyme. B: integrated optical densities were determined for phosphorylated ERK1/2. Results in (B) show the data in (A) normalized to the values observed at 0.5 mM Ca o 2ϩ (denoted as 1). The sums of P-ERK1 and P-ERK2 are shown. There was statistically significant stimulation at 2, 10, and 30 min (P Ͻ 0.05). Results are expressed as means Ϯ SE of the results from 4-5 separate experiments, each performed in duplicate.
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CAR REGULATION OF MAP KINASE in a maximal, sevenfold increase in combined ERK1 and ERK2 phosphorylation after a 10-min incubation.
Phosphorylation of ERK1/2 is mediated by the CaR in HEKCaR cells.
To prove the mediatory role of the CaR in activating MAPK, we compared the effects of elevated Ca o 2ϩ on MAPK activity in CaR-transfected and nontransfected HEK293 cells. As shown in Fig. 2 , A and B, addition of high Ca o 2ϩ to HEKCaR cells stimulated a rapid (within 2 min), dose-dependent phosphorylation of ERK1/2, which then began to decline after 30-60 min but persisted at a level above baseline for as long as 24 h. The high Ca o 2ϩ -stimulated phosphorylation of ERK1/2 in HEKCaR cells was markedly higher than that observed in nontransfected HEK293 cells (Fig. 2, A and B -elicited phosphorylation of ERK1/2 in parathyroid cells, we compared the effects of NPS R-467 with those of its less active enantiomer, NPS S-467, in parathyroid, HEKCaR, and HEK293 cells. NPS R-467 caused concentration-dependent increases in ERK1/2 phosphorylation in both HEKCaR and parathyroid cells (Fig. 3, A and B) . The R-enantiomer of NPS-467 was ϳ10-and 7-fold more potent, respectively, in HEKCaR and in parathyroid cells, than the S-enantiomer (Fig. 3, A-B) . To confirm the specificity of this compound for the CaR, we compared the effects of NPS R-467 in HEKCaR and HEK293 cells. NPS R-467 (3.0 M) increased ERK1/2 phosphorylation only in HEKCaR cells (not shown). , substantially lower than the value observed without NPS R-467 (e.g., Fig. 2) . These results support, therefore, the CaR's role in mediating the high-Ca o 2ϩ -evoked activation of ERK1/2 in both parathyroid and HEKCaR cells.
The role of PKC in CaR-mediated MAPK activation. To determine whether PKC mediates the activation of MAPK by the CaR, as is the case for several other GPCRs (17, (20) (21) (22) , we determined the effects of either activating PKC [by brief exposure to phorbol ester (phorbol 12-myristate 13-acetate, PMA)] or of inhibiting the enzyme with a PKC inhibitor. Figure 4 shows that, in cells preincubated for 10 min with PMA (1 M), there was a significant increase in high-Ca o 2ϩ -induced ERK1/2 phosphorylation in both cell types. Moreover, acute stimulation of PKC with PMA was sufficient to induce ERK1/2 phosphorylation at low Ca o 2ϩ (Fig. 4) . The MEK inhibitor PD98059 also abolished PMA-induced ERK1/2 activation in both cell types (not shown). Pretreatment of cells with the specific PKC inhibitor GF109203X (GFX; 0.1 M for 20 min), significantly inhibited 3.0 mM Ca o 2ϩ -stimulated phosphorylation of ERK1/2 in parathyroid (by 47%) and in HEKCaR cells (by 61%; Fig. 4 ), suggesting that PKC plays an important role in high Ca o 2ϩ -induced, CaR-mediated stimulation of ERK1/2 in these two cell types. Because inhibition of PKC only partially blocked high-Ca o 2ϩ -evoked activation of MAPK, however, it appeared likely that other intracellular signaling pathways also participated in this process.
Effect of protein tyrosine kinase and phosphatase inhibitors on high-Ca o 2ϩ
-stimulated MAPK activation. The Src family of tyrosine kinases have been implicated in activation of MAPK by several GPCRs (17) (18) (19) (20) (21) 32) . To examine whether Src or related tyrosine kinases might be linked to the high-Ca o 2ϩ -induced increases in ERK1/2 activities in parathyroid and HEKCaR cells, we tested the effects of herbimycin, a selective inhibitor of cytoplasmic tyrosine kinases (17, 21) . Herbimycin pretreatment for 20 min reduced highCa o 2ϩ -stimulated phosphorylation of ERK1/2 in both cell types, suggesting that c-Src, or a related cytoplasmic tyrosine kinase, may be a mediator in this signaling pathway (Fig. 4) . Genistein is another commonly used tyrosine kinase inhibitor (21, 41) . Pretreatment of parathyroid and HEKCaR cells with 1 g/ml genistein for 20 min also substantially inhibited high-Ca o 2ϩ -induced phosphorylation of ERK1/2 (Fig. 4) , whereas pretreatment with the phosphotyrosine phosphatase inhibitor, o-vanadate (100 M), enhanced this response in both cell types (Fig. 4) , suggesting the presence in these cells of a common signaling pathway involving tyrosine phosphorylation that participates in activation of MAPK (11, 50) .
MAPK activation is partially sensitive to PTX in parathyroid and HEKCaR cells. In several cell types, activation of ERK1/2 via G protein-coupled receptors has been reported to be sensitive to PTX (20, 41) . We therefore examined the effects of PTX on high Ca o 2ϩ -induced ERK1/2 phosphorylation in parathyroid and HEKCaR cells. PTX inhibited 3.0 mM Ca o 2ϩ -stimulated ERK1/2 phosphorylation by 65 and 60%, respectively, in parathyroid and HEKCaR cells (Fig. 4) . PTX preincubation was without effect on PMA-induced phosphorylation in HEKCaR cells (not shown), confirming that PKC activation of MAPK is G i independent. Because pretreatment of HEKCaR cells with PTX, or with PKC or protein tyrosine kinase (PTK) inhibitors individually, only partially reduced high-Ca o 2ϩ -induced ERK1/2 phosphorylation, we next examined the effects of various combinations of these inhibitors. As depicted in Fig. 5 , high-Ca o 2ϩ -stimulated ERK1/2 phosphorylation was almost completely inhibited by addition of combinations of two, and especially three, inhibitors.
The role of PI-PLC in CaR-mediated MAPK activation. Phosphoinositide (PI) hydrolysis produces IP 3 and diacylglycerol, leading to activation of PKC, which can stimulate MAPK activity. Figure 6 shows that a PI-PLC inhibitor (U73122) markedly diminished MAPK activation, and PTX enhanced this inhibitory effect on ERK1/2 phosphorylation, supporting the involvement of both G q/11 and G i in the CaR-activated MAPK cascade in HEKCaR cells.
Role of ERK1/2 in CaR-mediated stimulation of cPLA 2 phosphorylation in parathyroid and HEKCaR cells. In a previous study (24) , we showed that high Ca o 2ϩ (3.0 mM) stimulated cPLA 2 activity in parathyroid and HEKCaR cells, which is responsible for highCa o 2ϩ -evoked arachidonic acid release. Phosphorylation of cPLA 2 by ERK has been shown to be essential for its activation in several different systems (22, 29, 30) . Therefore, we investigated whether the 85-kDa PLA 2 was phosphorylated in response to activation of the CaR in parathyroid and HEKCaR cells by immunoprecipitating cPLA 2 after incubation of these cells with varying levels of Ca o 2ϩ or with NPS R-467 and then determining the extent of serine phosphorylation of cPLA 2 . As shown in Fig. 7 , the intensity of the band comigrating with cPLA 2 that is immunostained with an anti-phosphoserine antibody was greater in cells incubated with 3.0 mM Ca o 2ϩ or with NPS R-467. The specific MEK inhibitor PD98059 blocks the phosphorylation of ERK1/2 and several downstream cellular responses that are mediated via the MAPK cascade. This compound has been shown to inhibit specifically the upstream MAPK kinases (MEK1 and MEK2) that phosphorylate p42/p44 MAPK in several cell lines (10, 12, 28) . To study the role of ERKs in mediating the phosphorylation of cPLA 2 by high Ca o 2ϩ or by NPS R-467, we examined ERK1/2 and cPLA 2 phosphorylations in parathyroid and HEKCaR cells pretreated for 20 min with or without this compound. As shown in Fig. 7 , preincubation of parathyroid and HEKCaR cells with PD98059 for 20 min inhibited the phosphorylation of ERK1/2 and cPLA 2 induced by 3.0 mM Ca o 2ϩ or by NPS R-467. We next compared the role of PKC in the phosphorylation of ERK1/2 and cPLA 2 . In our previous study (24) , we showed that pretreatment of parathyroid cells with PMA stimulated release of arachidonic acid at low and high Ca o 2ϩ . Figure 8 shows that, in HEKCaR cells preincubated for 10 min with PMA (1 M), there was an immediate, statistically significant increase in the levels of phosphorylation of ERK1/2 and cPLA 2 at both low and high Ca o 2ϩ , showing that PKC mediates the activation of both. Figure 9 summarizes the mechanisms by which the CaR likely activates various signaling pathways and, in turn, MAPK and cPLA 2 in bovine parathyroid and HeKCaR cells. The subsequent metabolism of free arachidonic acid liberated by cPLA 2 generates a variety of active mediators, such as hydroxyperoxyeicosatetranoic acid and hydroxyeicosatetranoic acid. cell types with regard to the mechanisms underlying MAPK activation. In Rat-1 fibroblasts, for example, G i -coupled receptors mediate tyrosine kinase-dependent ERK1/2 activation (17). In Chinese hamster ovary cells, in contrast, stimulation of G q/11 -coupled receptors leads to ERK1/2 activation (23). In PC12 pheochromocytoma cells, both G i -and G q/11 -coupled receptors activate ERK1/2 (17, (19) (20) (21) . It is becoming increasingly clear that the pathways involved in MAP kinase activation are cell specific as well as agonist specific. We investigated, therefore, how high Ca o 2ϩ and the CaR regulate the MAPK cascade and, in turn, whether activation of MAPK is coupled to regulation of cPLA 2 in a CaR-dependent manner. Indeed, in the present study, we have demonstrated that high Ca o 2ϩ activates MAPK and promotes phosphorylation of cPLA 2 The CaR is activated by both polyvalent cations and polycationic molecules that interact with the extracellular domain of the receptor (6, 8, 9) . NPS R-467 and NPS R-568 are potent and selective activators of the Ca o 2ϩ -sensing receptor and inhibit both PTH secretion (38) and parathyroid cellular proliferation (42) . These compounds act as positive allosteric modulators to increase the sensitivity of the CaR to activation by Ca o 2ϩ and its other polycationic agonists and are thought to bind to the CaR's transmembrane domains (38) . The addition of NPS R-467 to parathyroid and HEKCaR cells produced a concentration-dependent increase in MAPK activity in the presence of 1.0 mM Ca o 2ϩ . The concentration-response curve for Ca o 2ϩ was also significantly left shifted in HEKCaR cells by the addition of NPS R-467, as has been shown previously for the regulation of PTH secretion and the cytosolic Ca 2ϩ concentration by Ca o 2ϩ (38) . Therefore, these results strongly support the mediatory role of the CaR in the activation of MAPK by high Ca o 2ϩ in bovine parathyroid cells.
Studies with other receptors have demonstrated two signaling pathways from GPCRs to the activation of MAPK, a PTX-sensitive, Ras-dependent pathway that requires G protein ␤␥-subunits and a PTX-insensitive, Ras-independent pathway that involves PKC (17) (18) (19) (20) (21) (22) (23) 41) . In HEK293 cells, ERK1/2 phosphorylation via endogenous lysophosphatidic acid (LPA) and thrombin receptors is mediated via both PTX-sensitive and -insensitive G proteins (17, 31, 32) . Chang et al. Fig. 1 . For analysis of cytosolic phospholipase A 2 (cPLA 2 ), parathyroid and HEKCaR cells were lysed in ice-cold lysis buffer, and after isolation of cell debris by centrifugation, the postnuclear supernatant was immunoprecipitated with monoclonal anti-cPLA 2 antibody followed by immunoblotting with anti-cPLA 2 and rabbit anti-phosphoserine antiserum, as described in EXPERIMENTAL PROCEDURES. Integrated optical densities were determined for phosphorylated ERK1/2 (C) and for phosphorylated cPLA 2 (D). Results are expressed as means Ϯ SE of the results from 3 separate experiments, each performed in duplicate.
insensitive increases of c-Src and ERK1 activity (36) . Thus ERK activation is complex and dependent not only on the nature of the receptor but also on the cell type.
Many factors stimulating the activity of phospholipases (e.g., PI-PLC, PC-PLC, PLA 2 , and/or PLD) also activate the phospholipid-dependent isoforms of PKC (6, 15, 24, 43) . In this study, we analyzed in detail the roles of PI-PLC and PKC in high-Ca o 2ϩ -induced MAPK activation in parathyroid and HEKCaR cells. Receptors that couple via G q/11 to phosphoinositide hydrolysis (such as the CaR) stimulate the formation of diacylglycerol and inositol phosphates and elevate the level of cytosolic Ca 2ϩ , leading to activation of PKC. In several cell types, the resultant activation of PKC plays an important role in MAPK stimulation (22, 41) . In parathyroid and HEKCaR cells, ERK1/2 activation by elevated Ca o 2ϩ also appears to be partially PKC dependent, because it was attenuated by the selective PKC inhibitor GF109203X. Moreover, acute stimulation of PKC with phorbol ester was sufficient to induce ERK1/2 phosphorylation in the presence of low Ca o 2ϩ . Elevated Ca o 2ϩ potentiated this effect of PMA, suggesting that multiple pathways are involved in ERK phosphorylation induced by the CaR. To characterize further the role of PI-PLC in MAPK activation, we studied the effect of U-73122, an aminosteroid inhibitor of PI-PLC activity (43, 45) , on high-Ca o 2ϩ -activated ERK1/2 phosphorylation. U-73122 inhibited both highCa o 2ϩ -and NPS R-467-induced activation of ERK1/2, documenting the role of PI-PLC in CaR-induced MAPK activation (most probably through a rise in intracellular calcium and/or activation of PKC).
The effects of PTK inhibitors on G i -coupled receptorand G-␤␥-subunit-mediated MAPK activation suggest a role for a PTK in the G-␤␥-mediated signaling pathway (31, 32) family and a member of an additional family, most likely G i , are both involved in this process (20, 21, 48) . Accordingly, we tested the effect of combinations of different inhibitors. In HEKCaR cells, the high Ca o 2ϩ -stimulated ERK1/2 phosphorylations were essentially completely inhibited by a combination of PTX, a PTK inhibitor (genistein), and a PKC inhibitor (GF109203X), supporting the involvement of multiple pathways in the activation of the MAPK cascade. Further studies are needed, however, to elucidate the mechanism underlying the CaR-mediated activation of MAPK occurring via the G i pathway, as well as the possible roles of other signaling cascades, including PI 3K, sphingomyelinase, LPA, PC-PLC, etc. (10, 13, 40) .
Bourdeau and colleagues (2, 3) showed that high Ca o 2ϩ increases the release of free arachidonic acid from parathyroid cells and that the addition of exogenous arachidonic acid or the products of its further metabolism, e.g., hydroxyperoxyeicosatetranoic acids, suppress PTH secretion, suggesting a role for PLA 2 activity in Ca o 2ϩ -regulated PTH release. Furthermore, Wang et al. (44) demonstrated that raising of Ca o 2ϩ or addition of neomycin, which also stimulates the CaR, reduces the activity of apical K ϩ channels in the thick ascending limb of the kidney. cPLA 2 is involved in the CaR-induced inhibition of K ϩ channel activity, since inhibition of cPLA 2 but not PLC abolishes this effect (43) . The mechanism by which the CaR activates cPLA 2 in the thick ascending limb, however, has not been investigated.
In many cell types, G protein-dependent signaling systems activate cPLA 2 via MAPK (20, 22, 29, 30 (24) . In both cell types, maximal highCa o 2ϩ -stimulated phosphorylation of ERK1/2 and arachidonic acid release occurred at the same concentration of Ca o 2ϩ (3.0 mM) and followed similar time courses. These data are consistent with the sequential activation of ERK1/2 and cPLA 2 . In the present studies, therefore, we investigated the possibility that cPLA 2 is phosphorylated and activated via MAPK. Using antibodies to the 85-kDa cytosolic form of PLA 2 and to phosphoserine, we found that cPLA 2 is phosphorylated on serine in parathyroid and HEKCaR cells and that the level of phosphorylation increases in high Ca o 2ϩ -stimulated cells and in the presence of PMA. Moreover, the inhibition of the ERK1/2 and cPLA 2 phosphorylation by the MEK inhibitor PD98059 indicates that ERK mediates this CaR-elicited activation of cPLA 2 in both cell types. Finally, activation of ERK1/2 and cPLA 2 is evident only in CaR-transfected HEK293 cells and not in nontransfected cells, providing strong evidence that the CaR directly or indirectly mediates these effects.
Cellular responses to external signals require coordinated control of protein kinases and phosphatases. In the case of ERK, the mechanisms underlying not only its activation but also its dephosphorylation and inactivation are of considerable interest, because phosphorylation occurs on both threonine and tyrosine residues during activation and because sustained ERK activation is important for proliferative signaling (12, 21, 28, 47) . To obtain evidence that dephosphorylation of ERK1/2 takes place in parathyroid and HEKCaR cells, we examined the effect of sodium orthovanadate, a potent inhibitor of protein tyrosine phosphatase that can serve in this fashion as a powerful activator of the Ras-Raf-MAPK cascade (28, 50) . Pretreatment of parathyroid and HEKCaR cells with sodium orthovanadate before addition of high Ca o 2ϩ potentiated the sustained phase of ERK1/2 phosphorylation in both cell types, suggesting that orthovanadate-sensitive phosphotyrosine phosphatase was the basis for ERK1/2 dephosphorylation in these cells. Further studies are needed ) mobilization, PKC activation, and resultant PKC-mediated stimulation of the mitogen-activating protein kinase (MAPK) cascade. The CaR also activates MAPK via a PTX-sensitive G protein, probably an isoform of G i , and subsequent downstream activation of a tyrosine kinase-dependent process, probably involving a Ras-and Raf-dependent series of steps. Activated MAPK then phosphorylates and activates cPLA 2 , which releases free arachidonic acid (AA) that can be metabolized to biologically active mediators such as hydroxyperoxyeicosatetranoic acid (HPETE) or hydroxyeicosatetranoic acid (HETE). *Data presented in this study.
to investigate the role of this phosphorylation in the control by MAPK of various aspects of the function of parathyroid, HeKCaR, and other CaR expressing cells.
We conclude that 1) elevated Ca o 2ϩ elicits rapid, dosedependent phosphorylation and activation of ERK1/2 in parathyroid and HEKCaR cells, but not in nontransfected HEK293 cells; 2) the CaR mediates activation of the MAPK cascade in parathyroid cells, because the selective CaR activator NPS R-467 mimics the effect of high Ca o 2ϩ ; 3) stimulation of the CaR by high Ca o 2ϩ and by NPS R-467 activates MAPK through multiple signaling pathways in both parathyroid and HEKCaR cells, including G q/11 -mediated activation of PI-PLC and PKC as well as a PTX-sensitive pathway likely involving G i , as has been described in various other cell types; and 4) the CaR mediates activation of cPLA 2 in HEKCaR and bovine parathyroid cells through the MAPK cascade.
